Welcome to the international HTA database

Showing [24117 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	HAYES, Inc.	Pneumatic compression for prevention of deep vein thrombosis following knee surgery
2001	Agency for Healthcare Research and Quality (AHRQ)	Pneumatic compression for treatment of chronic venous insufficiency and venous ulcers
2009	HAYES, Inc.	Pneumatic compression therapy for mastectomy-related lymphedema
2004	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Pneumatic compression therapy on venous insufficiency
2014	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal conjugate vaccine for children below five years old
2003	HAYES, Inc.	Pneumococcal conjugate vaccine for young children
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2020	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) for elderly
2003	Health Council of the Netherlands Gezondheidsraad (GR)	Pneumococcal vaccine in elderly adults and risk groups
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2020	National Institute for Health and Care Excellence (NICE)	PneuX to prevent ventilator-associated pneumonia. NICE medical technologies guidance 48
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	POCT/ Point of Care Tests: D-Dimer and Troponin
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care cholesterol testing for coronary heart disease: a review of the clinical effectiveness and guidelines
2020	Health Technology Wales (HTW)	Point of care haemolysis detection in blood samples that may be deemed unfit for laboratory analysis
2006	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Point of care testing - systematic review, expert panel
2001	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Point of care testing bed side system - systematic review, primary research, expert panel, working group
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Point of care testing bedside system (systematic review, primary research, expert panel, working group)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing compared to laboratory testing for the assessment of white blood cell counts and differentials: a review of the clinical effectiveness, diagnostic precision and accuracy, cost-effectiveness, and guidelines
2008	Adelaide Health Technology Assessment (AHTA)	Point of care testing for Coeliac disease
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing for human chorionic gonadotropin, creatinine, and blood urea nitrogen: cost-effectiveness
2008	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care testing for monitoring anticoagulation therapy
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing for streptococcal sore throat: a review of diagnostic accuracy, cost-effectiveness, and guidelines
2005	Agency for Healthcare Research and Quality (AHRQ)	Point of care testing of hemoglobin A1C
2006	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Point Of Care Testing System
2024	Austrian Institute for Health Technology Assessment (AIHTA)	Point of care tests (POCT): D-dimer and troponin (Update 2024)
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care ultrasound for guided central venous catheter insertion
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Point-of Care Ultrasound for Acute Respiratory Distress
2019	National Institute for Health and Care Excellence (NICE)	Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. NICE diagnostics guidance 37
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2014	Health Quality Ontario (HQO)	Point-of-care hemoglobin A1c testing: a budget impact analysis
2014	Health Quality Ontario (HQO)	Point-of-care hemoglobin A1c testing: an evidence-based analysis
2014	Health Quality Ontario (HQO)	Point-of-care hemoglobin A1c testing: OHTAC recommendation
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care HIV testing: a review of the clinical and cost-effectiveness and diagnostic accuracy
2008	Adelaide Health Technology Assessment (AHTA)	Point-of-care influenza diagnostic tests
2007	Adelaide Health Technology Assessment (AHTA)	Point-of-care influenza tests
2009	Medical Advisory Secretariat (MAS)	Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis
2007	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness
2012	Malaysian Health Technology Assessment (MaHTAS)	Point-Of-Care test for Chlamydia
2007	HAYES, Inc.	Point-of-care testing for glycated hemoglobin (A1c) using A1cNow (Metrika Inc.) for management of diabetes
2011	HAYES, Inc.	Point-of-care testing for glycated hemoglobin (A1c) using Bayer A1CNow+ multi-test A1C system (Bayer HealthCare LLC) for management of diabetes
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	Point-of-care testing in the private sector
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care testing: a review of systematic reviews on testing accuracy and cost-effectiveness
2019	European Network for Health Technology Assessment (EUnetHTA)	Point-of-care tests (POCT): D-dimer and troponin
2024	NIHR Health Technology Assessment programme	Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2010	HAYES, Inc.	Point-of-care thromboelastography and platelet function testing for management of perioperative transfusion therapy in cardiopulmonary bypass patients
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care troponin testing in patients with symptoms suggestive of acute coronary syndrome: a health technology assessment
2021	Health Technology Wales (HTW)	Point-of-care ultrasound to diagnose gallstone disease
1995	University HealthSystem Consortium (UHC)	Point-of-care whole-blood clinical analyzers
2024	Agency for Care Effectiveness (ACE)	Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2022	Agency for Care Effectiveness (ACE)	Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2023	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2020	European Network for Health Technology Assessment (EUnetHTA)	Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2004	Adelaide Health Technology Assessment (AHTA)	PoleStar (TM) N-10: intraoperative MRI for neurosurgical procedures
2009	Belgian Health Care Knowledge Centre (KCE)	Policies for rare diseases and orphan drugs
2009	Belgian Health Care Knowledge Centre (KCE)	Policies for rare diseases and orphan drugs
1999	TNO	Policy documents for the home care program
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Policy guidance on hip protectors in long-term care
2016	HAYES, Inc.	Polidocanol endovenous microfoam (Varithena) 1% for treatment of varicose veins
2022	Agency for Care Effectiveness (ACE)	Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2008	Canadian Agency for Drugs and Technologies in Health (CADTH)	Polyclonal intravenous immunoglobulin in patients with immune thrombocytopenic purpura: clinical systematic review
2009	HAYES, Inc.	Polyetheretherketone (PEEK) interbody cages for spinal fusion
2003	Adelaide Health Technology Assessment (AHTA)	Polyheme (R) and hemopure (R), blood substitute products: for the provision of emergency, short-term transfusion to trauma patients
2012	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Polylactic-glycolic acid absorbable synthetic suture (Pgla) plus antibacterial: a systematic review
1995	University HealthSystem Consortium (UHC)	Polymerase chain reaction
2007	HAYES, Inc.	Polymerase chain reaction (PCR) molecular testing for diagnosis of group B streptococcal infection in newborns
2007	HAYES, Inc.	Polymerase chain reaction (PCR)-based assays For methicillin-resistant staphylococcus aureus (MRSA) surveillance testing
2010	HAYES, Inc.	Polymerase Chain Reaction (PCR)-based assays for rapid diagnosis of clostridium difficile in hospitalized patients
2003	Medical Services Advisory Committee (MSAC)	Polymerase chain reaction in the diagnosis and monitoring of patients with AML1-ETO and CBF beta-MYH11 gene rearrangement in acute myeloid leukaemia
2004	Medical Services Advisory Committee (MSAC)	Polymerase chain reaction in the diagnosis and monitoring of patients with BCR-ABL gene rearrangement in acute lymphoblastic leukaemia
2003	Medical Services Advisory Committee (MSAC)	Polymerase chain reaction in the diagnosis and monitoring of patients with BCR-ABL gene rearrangement in chronic myeloid leukaemia
2003	Medical Services Advisory Committee (MSAC)	Polymerase chain reaction in the diagnosis and monitoring of patients with PML-RAR alpha and PLZF-RAR alpha gene rearrangement in acute promyelocytic leukaemia
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Polymerase chain reaction tests for methicillin-resistant staphylococcus aureus in hospitalized patients: clinical and cost-effectiveness analyses
2008	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	Polypharmacological treatment of type 2 diabetes in daily clinical practice - primary research, conference
2006	Medical Advisory Secretariat (MAS)	Polysomnography in patients with obstructive sleep apnea: an evidence-based analysis
2019	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 1: A rapid review
2020	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 2: use in Belgium
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Pomalidomide (Imnovid®)
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Pomalidomide for multiple myeloma – third line
2017	National Institute for Health and Care Excellence (NICE)	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib. NICE technology appraisal guidance 427
2019	National Institute for Health and Care Excellence (NICE)	Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 602
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ponatinib (Iclusig) for chronic myeloid leukaemia
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ponatinib (Iclusig®)
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Ponatinib for chronic myeloid leukaemia or Ph+ acute lymphoblastic leukaemia
2017	National Institute for Health and Care Excellence (NICE)	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2022	National Institute for Health and Care Excellence (NICE)	Ponesimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 767
2009	HAYES, Inc.	Pooled human thrombin or recombinant human thrombin versus bovine thrombin for surgical hemostasis
2003	Adelaide Health Technology Assessment (AHTA)	Population genetic screening for haemochromatosis: identifying asymptomatic "at risk" homozygous individuals
2012	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: accelerated repeat screening for bowel cancer
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: bowel cancer screening by pill camera
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: calcium score and the risk of cardiovascular disease
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: Continuing a population screening trial
2014	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: first trimester scan for prenatal screening
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: mammography in two directions as standard
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: national population screening programme for bowel cancer
2013	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: noninvasive prenatal test for increased risk of trisomy
2011	Health Council of the Netherlands Gezondheidsraad (GR)	Population screening act: prostate cancer screening using MRI
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: risk stratification based on familial risk of bowel cancer